E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer ; volume:4 ; number:1 ; day:11 ; month:1 ; year:2018 ; pages:1-5 ; date:12.2018
npj Breast cancer ; 4, Heft 1 (11.1.2018), 1-5, 12.2018
- Keyword
-
Krebs
Onkologie
- Creator
-
Yeruva, Sri Lakshmi Hyndavi
- Contributor
-
Zhao, Fengmin
Miller, Kathy D.
Tevaarwerk, Amye J.
Wagner, Lynne I.
Gray, Robert J.
Sparano, Joseph A.
Connolly, Roisin M.
SpringerLink (Online service)
- DOI
-
10.1038/s41523-017-0053-3
- URN
-
urn:nbn:de:1111-201803032115
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yeruva, Sri Lakshmi Hyndavi
- Zhao, Fengmin
- Miller, Kathy D.
- Tevaarwerk, Amye J.
- Wagner, Lynne I.
- Gray, Robert J.
- Sparano, Joseph A.
- Connolly, Roisin M.
- SpringerLink (Online service)
Other Objects (12)
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Rat Models of Hormone Receptor-Positive Breast Cancer
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Rat Models of Hormone Receptor-Positive Breast Cancer
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Rat Models of Hormone Receptor-Positive Breast Cancer
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials